An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010606-10

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary statistical objective is to describe differences between Travoprost APS and XALATAN® for mean NEI VFQ-25 composite (Visual Function) score at the end of the three-month treatment period in patients with open-angle glaucoma or ocular hypertension.


Critère d'inclusion

  • open-angle glaucoma or ocular hypertension